Jul 27, 2021 7:00am EDT Tonix Pharmaceuticals Announces Agreement to Acquire Infectious Disease R&D Facility to Accelerate Development of Vaccines and Antiviral Drugs
Jul 23, 2021 4:40pm EDT Tonix Pharmaceuticals Announces Outcome of Interim Analysis of Phase 3 RALLY Study of TNX-102 SL for the Management of Fibromyalgia
Jun 21, 2021 7:00am EDT Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC)
Jun 16, 2021 7:00am EDT Tonix Pharmaceuticals to Present at Raymond James Human Health Innovation Conference
Jun 3, 2021 7:00am EDT Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 26, 2021 7:00am EDT Tonix Pharmaceuticals Announces Presentation of Two Posters at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
